Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products

Biologicals

Volumn 42, Issue 5, 2014, Pages 260-270

  Germishuizen, W A ^a   Gyure, D C ^a   Stubbings, D ^a   Burnouf, T ^b  

^a National Bioproducts Institute   (South Africa)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

FXIa; IVIG; Procoagulant; SCIG; Thrombosis

Indexed keywords

ALCOHOL; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 11A; CARDIOLIPIN ANTIBODY; CD40 LIGAND; CYCLIC AMP DEPENDENT PROTEIN KINASE; IMMUNOGLOBULIN G; MACROGOL; OCTANOIC ACID; PLASMA PROTEIN; PREKALLIKREIN; PROCOAGULANT; PROTHROMBIN; THROMBOPLASTIN; BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ANALYTIC METHOD; ANAPHYLAXIS; ASEPTIC MENINGITIS; BLOOD VISCOSITY; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG CONTAMINATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG PURITY; DRUG RECALL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FOOD AND DRUG ADMINISTRATION; FRACTIONATION; HEART INFARCTION; HUMAN; ION EXCHANGE CHROMATOGRAPHY; LABORATORY TEST; LUNG EMBOLISM; MONOCYTE; NEUTROPENIA; PARTIAL THROMBOPLASTIN TIME; PASTEURIZATION; PRECIPITATION; PROCESS MONITORING; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; REVIEW; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOGENICITY; ULTRAFILTRATION; UNITED STATES; VEIN THROMBOSIS; ANIMAL; BLOOD; IMMUNOLOGY; ISOLATION AND PURIFICATION; MEDICINAL CHEMISTRY; PREVENTION AND CONTROL; RISK ASSESSMENT; STANDARDS;

ANIMALS; BIOLOGICAL PRODUCTS; BLOOD COAGULATION FACTORS; CHEMISTRY, PHARMACEUTICAL; DRUG CONTAMINATION; FACTOR XIA; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 84908151408     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2014.04.002     Document Type: Review

References (56)

1. Daniel G.W., Menis M., Sridhar G., Scott D., Wallace A.E., Ovanesov M.V., et al. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion 2012, 52:2113-2121.
2. Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005, 29:173-184.
3. Radosevich M., Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010, 98:12-28.
4. Dhainaut F., Guillaumat P.-O., Dib H., Perret G., Sauger A., de Coupade C., et al. Invitro and invivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang 2013, 104:115-126.
5. Ma L., Sun P., Lin F.Z., Diao G., Li C.Q. Quantitative determination of activated coagulation factor XI as an impurity in therapeutic immunoglobulins from Chinese blood fractionation companies. Genet Mol Res 2013, 12:2556-2561.
6. Stoclin A., Delbos F., Dauriat G., Brugiere O., Boeri N., Metivier A.C., et al. Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient. Vox Sang 2013, 104:175-178.
7. Rizk A., Gorson K.C., Kenney L., Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001, 41:264-268.
8. Cohn E., Strong L., Hughes W., Mulford D., Ashworth J., Melin M., et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. JAm Chem Soc 1946, 68:459-475.
9. Kistler P., Nitschmann H. Large scale production of human plasma fractions. Eight years' experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962, 7:414-424.
10. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007, 21:101-117.
11. ® manufacturing process. Immunotherapy 2011, 2:WMC002002.
12. FDA (U.S.Food and Drug Administration) Octagam (immune globulin intravenous (human)) 5% liquid preparation: market withdrawal - risk of thromboembolic events 2010, US Food and Drug Administration, Bethesda.
13. European Medicines Agency European Medicines Agency recommends suspension of Octagam in all EU member states. CHMP recommendation based on risk of thromboembolic reactions 2010 Sep 24, Report No.: EMA/CHMP/591722/2010.
14. European Medicines Agency Questions and answers on the recommendation to lift the suspension of Octagam (human normal immunoglobulin 5% and 10%) 2011, published 14 April 2011, EMA/293780/2011.
15. Funk M.B., Gross N., Gross S., Hunfeld A., Lohmann A., Guenay S., et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013, 106:54-64.
16. Wolberg A., Kon R.H., Monroe D.M., Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000, 65:30-34.
17. Alving B.M., Tankersley D.L., Mason B.L., Rossi F., Aronson D.L., Finlayson J.S. Contact-activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive properties. JLab Clin Med 1980, 96:334-346.
18. Etscheid M., Breitner-Ruddock S., Gross S., Hunfeld A., Seitz R., Dodt J. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang 2011, 102:40-46.
19. FDA (U.S.Food and Drug Administration) Important safety information: risk of thrombotic adverse events with subcutaneous or inappropriate intravenous use of vivaglobin (immune globulin subcutaneous) 2011, US Food and Drug Administration, Bethesda.
20. Breitner-Ruddock S., Dodt J., Etscheid M., Gross S., Grundmann C., Hunfeld A., et al. Laboratory investigations of intravenous immunoglobulin (IVIG) products associated with thromboembolic events. Public workshop on risk mitigation strategies to address procoagulant activity in immune globulin products by U.S. Food and Drug Administration Plasma Protein Therapeutics Association (PPTA), Department of Health and Human Services, held on 17 May 2011 in Rockville, MD, USA 2011.
21. European Pharmacopoeia Commission - Council of Europe European Department for the Quality of Medicines Monograph on human normal immunoglobulin for intravenous administration (0918): 01/2012, European Pharmacopoeia 2012, Council of Europe, Strasbourg (France).
22. European Pharmacopoeia Commission - Council of Europe European Department for the Quality of Medicines Monograph on human normal immunoglobulin (0338). European Pharmacopoeia 2012, Council of Europe, Strasbourg (France).
23. FDA (U.S.Food and Drug Administration) FDA safety communication: new boxed warning for thrombosis related to human immune globulin products 2013, US Food and Drug Administration, Bethesda. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm375096.htm.
24. Sridhar G., Ekezue B.F., Izurieta H.S., Selvam N., Ovanesov M.V., Divan H.A., et al. Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012. Transfusion 2014, 10.1111/trf.12663.
25. Marie I., Maurey G., Hervé F., Hellot M.F., Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006, 155:714-721.
26. Menis M., Sridhar G., Selvam N., Ovanesov M.V., Divan H.A., Liang Y., et al. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011. Am J Hematol 2013, 88:1035-1040.
27. Lackner F., Beck G., Eichmeir S., Gemeiner M., Hummel K., Pullirsch D., et al. Contamination of therapeutic human immunoglobulin preparations with apolipoprotein H (β2-glycoprotein I). Electrophoresis 2014, 35:515-521.
28. Duronio A., Bajjoka I., Hsaiky L., Parasuraman R. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients. Ann Pharmacother 2007, 41:354-358.
29. Reinhart W.H., Berchtold P.E. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992, 339:662-664.
30. Baba R. Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease. Recent Pat Cardiovasc Drug Discov 2008, 3:141-144.
31. Dalakas M.C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994, 44:223-226.
32. Stratta P., Canavese C., Schinco P.C., Montaruli B., Giorda L., Bessone P., et al. Intravenous immunoglobulin contains detectable amounts of antiphospholipid antibodies. Br J Haematol 1997, 96:872-882.
33. Thompson C.A. One IVIG mystery solved, another demands vigilance. Am J Health Syst Pharm 2012, 69:271-272.
34. Salge-Bartels U., Heiden M., Groß N., Seitz R. Significance of platelet and monocyte activation for therapeutic immunoglobulin-induced thromboembolism. Thromb Res 2014, 133:244-253.
35. Lebing W., Remington K.M., Schreiner C., Paul H.I. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 2003, 84:193-201.
36. Parkkinen J., Rahola A., Von Bonsdorff L., Tolo H., Torma E. Amodified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox Sang 2006, 90:97-104.
37. Wu Y.-W., Champagne J., Toueille M., Gantier R., Burnouf T. Dedicated removal of immunoglobulin (Ig)A, IgM, and factor (F)XI/activated FXI from human plasma IgG. Transfusion 2013, 10.1111/trf.12243.
38. Marzo N., Jose M., Lopez L., Bono M., Lopez M., Jorquera J.I. Quantitative determination of relevant amounts of blood coagulation factor XI activity in a specific brand of intravenous immunoglobulin. Immunotherapy 2011, 5:WMC001922.
39. Seligsohn U. Factor XI in haemostasis and thrombosis: past, present and future. Thromb Haemost 2007, 98:84-89.
40. Jose M., Marzo N., Bobo M., Carretero M., Maite L., Ristol P., et al. Pasteurization inactivates clotting enzymes during Flebogamma and Flebogamma Dif production. Immunotherapy 2010, 1:WMC001425.
41. Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy 2005, 25:78S-84S.
42. ® purification process to deplete thrombogenic factor XIa from plasma. Vox Sang 2014, 1111/vox.12119.
43. Turecek PL. Minimizing Procoagulant Impurities in IGIV Products Baxter's Approach FDA. U.S. Food and Drug Administration. Risk Mitigation Strategies to Address Potential Procoagulant Activity in Immune Globulin Products. Public Workshop; Rockville, MD, US. May 17-18, 2011.
44. Burnouf-Radosevich M., Burnouf T. Atherapeutic highly purified factor XI concentrate from human plasma. Transfusion 1992, 32:861-867.
45. Burnouf T., Radosevich M. Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. JBiochem Biophys Methods 2001, 49:575-586.
46. Grundmann C., Kusch M., Keitel S., Hunfeld A., Breitner-Ruddock S., Seitz R., et al. Modified thrombin generation assay: application to the analysis of immunoglobulin concentrates. Immunotherapy 2010, 11:WMC001116.
47. Liang Y., Woodle S.A., Shibeko A.M., Lee T.K., Ovanesov M.V. Correction of microplate location effects improves performance of the thrombin generation test. Thromb J 2013, 11:1-9.
48. European Pharmacopoeia Commission - Council of Europe European Department for the Quality of Medicines. European Pharmacopeia 7.0, 2.6.22, activated coagulation factors 2008, Report No.: 01/2008:20622.
49. Thomas D.P., Merton R.E., Gray E., Barrowcliffe T.W. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemost 1989, 61:204-207.
50. Wessler S., Reimer S.M., Sheps M.C. Biologic assay of a thrombosis inducing activity in human serum. JAppl Physiol 1959, 14:943-946.
51. Gray E., Wilmot H., Hogwood J., Rigsby P. Evaluation of the proposed WHO 1st reference reagent for activated blood coagulation factor XI (FXIa), Human 15 to 19 October 2012, WHO Expert Committee on Biological Standardization, Geneva, WHO/BS/2012.2206, 2012.
52. National Institute for Biological Standards and Control. WHO Reference Reagent, 1st International Reference Reagent for Activated Blood Coagulation Factor XI (FXIa), Human NIBSC code: 11/236. http://www.nibsc.org/products/biological_reference:materials/product_catalogue/detail_page.aspx?catid=11/236.
53. European Pharmacopoeia Commission - Council of Europe European Department for the Quality of Medicines Human prothrombin complex monograph (554), European Pharmacopoeia 2009, Council of Europe, Strasbourg (France).
54. Roemisch J.R., Zapfl C., Zoechling A., Pock K. Comparison of thrombin generation assay (TGA) and non-activated partial thromboplastin time (NAPTT) for the assessment of enhanced procoagulant activity in immunoglobulin solutions. Immunotherapy 2012, 3:WMC003247.
55. Seifner A., Beck G., Bayer P., Eichmeir S., Lackner F., Rögelsperger O., et al. Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography. Transfusion 2013, 10.1111/trf.12280.
56. Putz M. Animal models - predictive value; Wessler and other models. FDA. U.S. Food and Drug Administration. Risk Mitigation Strategies to Address Potential Procoagulant Activity in Immune Globulin Products. Public Workshop; Rockville, MD, US. May 17-18, 2011.